2026 CBG Human Study: What 12 Participants Tell Us

Interest in cannabigerol, or CBG, has moved faster than human research on it. A study published online July 11, 2026 took a basic but useful step: measuring what happened after healthy adults received single oral doses of CBG under controlled conditions. The paper appeared in the August 2026 issue of The Journal of Pharmacology and Experimental Therapeutics.

The study is news because it addresses a gap in the evidence. It is not a test of whether CBG treats a condition or improves a daily routine, and it did not test Jane's Brew products. Published research often begins with these basic measurements before larger trials examine longer use or specific outcomes. That sequence matters when interpreting a promising headline.

What the researchers tested

Twelve healthy adults took part in a single ascending dose laboratory study. The tested doses were placebo and 25, 50, 100, and 200 milligrams of CBG isolate suspended in medium-chain triglyceride oil. Researchers recorded adverse events, measured CBG in blood samples, and checked subjective, cognitive, and physiological responses over eight hours. They also assessed liver function after the two highest doses.

This design helps describe short-term exposure and response across the particular doses and formulation studied. It does not mimic repeated use over weeks or months. The CBG was an isolate delivered in oil, not a water-dispersible drink powder.

What the paper found

The authors reported no drug-related adverse events during the study and no liver test values above the normal upper limit after the highest acute doses. Subjective effects were generally small. A few individual ratings changed at specific doses: participants reported lower “jittery” and “active” ratings at 50 milligrams, lower “calm” ratings at 100 milligrams, and higher appetite ratings at 200 milligrams.

Blood measurements generally increased with dose, but responses varied considerably from one participant to another. That variability is one reason a stated milligram amount should not be read as a guarantee of a particular feeling or timing. The authors' overall conclusion was that more studies using repeated dosing are needed to characterize CBG's safety and effects more fully.

What this means for CBG shoppers

The study provides early human data; its small size, single-dose design, and oil-based isolate limit how far it can be applied. It cannot establish long-term safety, prove a benefit, or predict the experience of someone taking a different formulation. Jane's Brew's Nano CBG Powder is labeled at 30 milligrams CBG per scoop, but this research does not test that product or its delivery system.

For now, the useful habit is to read the specific product's cannabinoid and serving information, follow its package directions, and treat emerging CBG headlines as evidence in progress. Future larger and longer human studies can answer questions this first short-term study was not built to address.